{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-000999","form_type":"8-K","ticker":"RLMD","cik":"0001553643","company_name":"RELMADA THERAPEUTICS, INC.","filed_at":"2024-01-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.586712+00:00","generated_at":"2026-06-07T03:56:28.430338+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Relmada provides 2024 outlook: REL-1017 study 302 ~50% enrolled; psilocybin Phase 1 planned","bullets":["REL-1017 Phase 3 study 302 (Reliance II) is approximately 50% enrolled (target ~300 patients); full enrollment expected H1 2024.","REL-1017 Phase 3 study 304 (Relight) enrollment to complete by year-end 2024, also ~300 patients.","Phase 1 trial of modified-release psilocybin (REL-P11) in obese patients with steatotic liver disease to start H1 2024; Phase 2a data expected H1 2025.","Dr. Cedric O'Gorman steps down as CMO; Dr. Andrew Cutler appointed Senior Clinical Development Advisor to support NDA process.","Cash runway expected to extend beyond all 2024 catalysts; no specific cash balance disclosed."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-000999","json":"https://secwatch.observer/filing/0001213900-24-000999.json","markdown":"https://secwatch.observer/filing/0001213900-24-000999.md","text":"https://secwatch.observer/filing/0001213900-24-000999.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1553643/000121390024000999/0001213900-24-000999-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1553643/000121390024000999/ea191114-8k_relmada.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T03:56:28.430338+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}